SCHEMBL5120322

SCHEMBL5120322

CCOC1Oc2c(c(=O)oc3cc(C)c(C)cc23)C1c1c(O)c2cc(C)c(C)cc2oc1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO1 P15559 10/20 0.46
ALDH1A1 P00352 4/20 0.34
KDM4E B2RXH2 4/20 0.34
HPGD P15428 3/20 0.34
HSD17B10 Q99714 3/20 0.34
TSHR P16473 2/20 0.34
GLA P06280 1/20 0.31
GAA P10253 1/20 0.31
CASP1 P29466 1/20 0.31
CASP7 P55210 1/20 0.31
ADORA3 P0DMS8 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
JAK2 O60674 1/20 0.30
JAK1 P23458 1/20 0.30
TYK2 P29597 1/20 0.30
JAK3 P52333 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP2C19 P33261 1/20 0.30
HSD17B3 P37058 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5117858 0.87 NQO1 (0.46) NQO1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL5111977 0.87 NQO1 (0.48) NQO1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL5119698 0.85 PRNP (0.40) NQO1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL5115619 0.84 NQO1 (0.38) NQO1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL5115168 0.84 NQO1 (0.47) NQO1ALDH1A1KDM4ETSHR
SCHEMBL5118330 0.84 CA12 (0.46) NQO1ALDH1A1TSHR
SCHEMBL5125494 0.84 NQO1 (0.47) NQO1ALDH1A1MEN1KMT2A
SCHEMBL5114980 0.83 NQO1 (0.52) NQO1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL5125455 0.81 TP53 (0.38) NQO1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL14172459 0.81 NQO1 (0.49) NQO1ALDH1A1KDM4EHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7384975-B2 Substituted furochromenes, preparation thereof and their antiinflammatory action GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) 2008-06-10 US disclosed
US-20060148889-A1 Substituted furochromenes, preparation thereof and their antiinflammatory action PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) 2006-07-06 US disclosed
EP-1648902-A1 SUBSTITUTED FUROCHROMENES, PREPARATION THEREOF AND THEIR ANTIINFLAMMATORY ACTION PLIVA-ISTRAZIVACKI INSTITUT d.o.o. (HR) 2006-04-26 EP disclosed
WO-2005010007-A1 SUBSTITUTED FUROCHROMENES, PREPARATION THEREOF AND THEIR ANTIINFLAMMATORY ACTION PLIVA- ISTRAZIVACKI INSTITUT D.O.O. (HR) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148889-A1 Substituted furochromenes, preparation thereof and their antiinflammatory action CYP11B2, CYP11B1, LTC4S NQO1 60/4885ALDH1A1 486/4885KDM4E 3765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.